Table 3.
Response rates.
| Any reaction N(%) |
Severe Reaction N(%) |
Medically attended | Follow-up | Gender/Sex N(%) |
Age | Race/Religion/Cultural Group N(%) |
Vaccine type N(%) |
|
|---|---|---|---|---|---|---|---|---|
| Alhowaymel et al.17 - Saudi Arabia | 174/222(78.4) | N/A | N/A | N/A |
M–165(74.3) F–57(25.7) |
N(%) 18–29: 66(29.8) 30–40: 68(30.6) 41–51: 60(27.0) >52: 28(12.6) |
Saudi-138(62.2) Non-Saudi-84(37.8) |
AZ- 222(100) |
| Amodio et al.18 - Italy | 242/293(82.6) | N/A | N/A | Seven questionnaires sent for a week following first and second dose | F − 134/293(45.7) M − 159/293(54.3) |
Median(IQR) 36(29–52) |
N/A | Pfizer 293(100) |
| Angkasekwinai et al.19 - Thailand | CoronaVac v ChAdOx1 1st dose 152/180(84.4) vs. 119/180(66.1) CoronaVac v ChAdOx1 2nd dose 136/180(75.6) vs. 109/180(60.6) |
0(0) | N/A | 7 days after vaccination | F − 303(84.2) M − 57(15.8) |
Median(IQR) 35(29–44) |
N/A | CoronaVac 180(50) ChAdOx1 180(50) |
| Azzolini et al.20 - Italy | 1621/4156 | N/A | 8/2211 events(0.36) | 10 days after 2nd dose | M − 1589(38) F − 2567(62) |
Median 37 IQR 27–48 | N/A | Pfizer 4156(100) |
| Beatty et al.21 - United States | 1 dose of BNT162b2 or mRNA-1273 5629/8680(64.9) 2 doses of BNT162b2 or mRNA-1273 or 1 dose of JNJ-78436735 8947/11140(80.3) |
1 dose of BNT162b2 or mRNA-1273 26/8680(0.3) 2 doses of BNT162b2 or mRNA-1273 or 1 dose of JNJ-78436735 27/11140(0.2) |
N/A | Monthly surveys from January 14 – May 19, 2021 | M − 6024/19586(30.9) F – 13,281/19586(68.1) Transgender- 46/19586(0.23) Genderqueer-110/19586(0.6) Other-60/19586(0.3) |
Median (IQR) 54 (38–66) |
American Indian or Alaska Native 286(1.5) Asian 1506(7.8) Black 443(2.3) Native Hawaiian/Pacific Islander 87(0.4) White 17294(89.4) Other/Unknown 617(3.2) Hispanic 1476(7.6) |
Did not separate out for each |
| Bettinger et al.22 - Canada | 234174/683847(34.2) | 2055/683847(0.3) | 10092/683847(1.5) | 8 days after each of 3 doses sent questionnaire | M − 291144/683847(42.6) F − 391528/683847(57.3) Intersex/Decline − 1175/683847(0.17) |
20–29: 72750(10.6) 30–39: 111493(16.3) 40–49: 66067(9.7) 50–64: 138524(20.3) 65–79: 160767(23.5) 80+:23246(3.4) |
Black 2947/369351(0.8) Asian 9204/369351(2.5) Indigenous 1909/369351(0.5) Latino 3512/369351(0.9) Arabic 3871/369351(1.0) Indian/Pakistani 6188/369351(1.7) Southeast Asian 3503/369351(0.9) White 215626/369351(58.4) Mixed 5491/369351(1.5) Other/Unknown 112262/369351(30.4) Declined 4838/369351(1.3) |
Pfizer 369406(54) Moderna 201314(29.4) AZ 113127(16.5) |
| Briggs et al.23 - USA | 1st dose 459/719(63.8) 2nd dose 327/442(74.0) |
1st dose 122(16.9) 2nd dose 99(22.4) |
N/A | N/A | 1st dose F − 608(84.6) M − 111(15.4) 2nd dose F- 371(83.9) M-71(16.1) |
Mean(SD) 1st dose 53.0 (SD 11.8) 2nd dose 53.5 (SD 12.2) |
1st dose White − 677(94.2) Non-white − 32(4.4) Unknown − 10(1.4) 2nd dose White − 419(94.6) Non-white − 21(4.8) Unknown − 3(0.7) |
1st dose Pfizer-409(56.9) Moderna-258(35.9) Johnson-31(4.3) AZ-20(2.8) Other-1(0.1) 2nd dose Pfizer-269(60.9) Moderna-166(37.6) Johnson-0(0) AZ-6(1.4) Other-1(0.2) |
| Bsoul et al.24 - USA | 296(78) | 30(8) | N/A | N/A | F − 241(64) M- 134(35) Prefer not to answer − 4(1) |
18–24:56(15)25–34:101(27) 35–44:51(13)45–54:58(15)55+:113(30) |
Asian:62(16) Black:10(3)Hispanic:124(33) Other:12(3)White:171(45) |
Pfizer 379(100) |
| Chalermphanchai et al.25 - Thailand | 20/42(47.6) | 0(0) | N/A | Followed for 30 days | M − 12(28.3) F − 30(71.4) |
Mean 48 Range 23–62 |
N/A | Pfizer 42(100) |
| Cuschieri et al.26 - Italy | 34–1316/1480(2.3–88.9) across several symptoms | 2–186/1480(0.1–12.6) across several symptoms | N/A | Not specified | M − 493(33.3) F − 987(66.7) |
18–24 144(9.7) 25–34 474(32) 35–44 291(19.7)45–54 328(22.2)55–64 235(15.9)65+ 80(5.4) |
N/A | Pfizer 4885(100) |
| D’Arminio Monforte et al.27 - Italy | First dose 1836/3078(59.6) Second dose 2238/3049(73.4) |
0(0) | 0(0) | Two weeks after 2nd dose | F − 1980/3078(64.3) M − 1098/3078(35.7) |
Median(IQR) 47(34–56) |
Italian 2856(92.8) Other 222(7.2) |
Pfizer 3078(100) |
| Deng et al.28 - Australia | Pfizer Dose 1–483 003/1 346 308(35.9) Pfizer Dose 2–521 748/953 704(54.7) AZ Dose 1 - 228 685/433 427(52.8) AZ Dose 2 - 66 726/302 544(22.0) |
N/A | Pfizer Dose 1–8699/1 346 308(0.65) Pfizer Dose 2–13 073/953 704(1.4) AZ Dose 1–5260/433 427(1.2) AZ Dose 2–1266/302 544(0.42) |
N/A | Pfizer Dose 1 M: 160 764/565 158(28.4) F: 320 712/777 187(41.3) Other: 782/1700 (46) Pfizer Dose 2 M: 181 950/399 392(45.6) F: 338 101/551 535(61.3) Other: 690/1021(68) AZ Dose 1 M: 93 652/199 643(46.9) F: 133 113/230 019(57.9) Other: 199/285(70) AZ Dose 2 M: 23 052/136 689(16.9) F: 43 174/163 831(26.4) Other: 40/92 (44) |
Median (IQR) Pfizer Dose 1 42 (33–49) Pfizer Dose 2 44 (37–49) AZ Dose 1 61 (52–68) AZ Dose 2 62 (54–70) |
Pfizer Dose 1 Indigenous7443/20 245(36.8) Non-indigenous 467 856/1 303 080(35.9) Pfizer Dose 2 Indigenous 6447/12 228(52.7) Non-indigenous 498 268/910 202(54.7) AZ Dose 1 Indigenous 2230/4 551(49.0) Non-indigenous 219 938/416 314(52.8) AZ Dose 2 Indigenous 625/3019(20.7) Non-indigenous 62 624/284 443(22.0) |
Pfizer Dose 1 1 346 308/3 035 983(44.3) Pfizer Dose 2 953 704/3 035 983(31.4) AZ Dose 1 433 427/3 035 983(14.3) AZ Dose 2 66 726/3 035 983(2.2) |
| Ebinger et al.29 - USA | After dose 1 614/1032(60.0) After dose 2 752/1032(73.6) |
N/A | N/A | N/A | F − 691(67.4) M − 341(32.6) |
Average Age (SD) 43.3(12.6) |
Non-Hispanic Asian 280(27.1) Non-Hispanic Black 33(3.2) Non-Hispanic White 493(47.8) Hispanic/Latinx 126(12.2) Other 100(9.7) |
Pfizer 1032(100) |
| Figueroa et al.30 - Mexico | First dose 68/79(86) Second dose 64/79(81) |
First dose 0(0) Second dose 0(0) |
N/A | N/A | F − 51(64.6) M- 28(35.4) |
Median 42 years (IQR 35–46) | Mexican 79(100) |
Pfizer 79(100) |
| Lai et al.31 - Hong Kong | 80/160(50) | N/A | N/A | N/A | F − 90/160(56.25) M − 70/160(43.75) |
21–78 Median 40 |
N/A | Pfizer 160(100) |
| Gepner et al.32 - Israel | 422/1323(31.9) | 1/625(0.16) | 2/625(0.32) Hospitalization |
Followed up at the end of 1st and 2nd week after vaccination | M − 676(51.1) F − 647(48.9) |
<30: 239/422(56.6) 30–59: 169/422(39.8) 60+: 14/422(3.6) |
N/A | Covishield 1323(100) |
| Goldlin et al.33 - India | Second vaccine 102/355(30.4) Third vaccine 404/1179(34.2) |
Second vaccine 52(15.6) Third vaccine 120(10.2) |
N/A | N/A | Second vaccine M − 149 (42.1) F − 206(57.9) Third vaccine M − 512(43.4) F − 667(56.6) |
Second vaccine Average 51.8 Third vaccine 50.0 |
N/A | Second vaccine 355(100) Third vaccine 1179(100) |
| Guan et al.34 - Israel | 212/255(83.1) | 0(0) | 0(0) | Followed for 6 months after completing vaccine schedule | F − 144(56.5) M − 111(43.5) |
Mean(SD) 40.7(11.4) |
N/A | AZ 255(100) |
| Hammad et al.35 - Egypt | First dose 199/232(85.78) Second dose 136/232(58.62) |
N/A | N/A | N/A | M − 26(11.21) F − 206(88.79) |
Average 39(SD 9.97) |
N/A | AZ 232(100) |
| Hyun et al.36 - Korea | First dose 1450/1586(91.4) Second dose 1194/1306(91.4) |
First dose 0(0) Second dose 0(0) |
N/A | N/A | First dose M − 522/1586(32.9) F − 1064/1586(67.1) Second dose M − 388/1306(29.7) F − 918/1306(70.3) |
First dose 20–29546 (34.4%) 30–39402 (25.3%) 40–49336 (21.2%) 50–59220 (13.9%) 60–82 (5.2%) Second dose 20–29 427 (32.7%) 30–39 321 (24.6%) 40–49 288 (22.1%) 50–59 197 (15.1%) 60- 73 (5.6%) |
N/A | Pfizer First dose 1586(100) Second dose 1306(100) |
| Inoue et al.37 - Japan | 1st dose 975/994(98.1) 2nd dose 661/727(90.9) |
1/994(0.1) | 1st dose 13/994(1.3) 2nd dose 5/727(0.7) |
7 days following vaccination | 1st dose F − 762(76.7) M − 232(23.4) 2nd dose F − 559(76.9) M − 168(23.1) |
1st dose Mean 35.7 Range 19–63 2nd dose Mean 36.7 Range 20–63 |
N/A | AZ 1384(100) |
| Javed et al.38 - Saudi Arabia | 324/564(57.4) | 0(0) | N/A | 15–20 days Google Forms after vaccination | M − 210(37.2) F − 354(62.8) |
25 and below:108(18.4) 26–35:288(51.1) 36–45:110(19.5) 45+:62(11) |
N/A | AZ 564(100) |
| Jeon et al.39 - South Korea | Pfizer Dose 1 Local reactions: 996/1406(70.8) Systemic reactions: 850/1406(60.5) Pfizer Dose 2 Local reactions: 849/1168(72.7) Systemic reactions: 1010/1168(86.5) AZ Local reactions: 1195/1679(71.2) Systemic reactions: 1501/1679(89.4) |
N/A | Pfizer Dose 1 26/1406(1.8) Pfizer Dose 2 38/1168(3.3) AZ 143/1679(8.5) |
Not specified | F − 3216/4253(75.6) M − 1037/4253(24.4) |
20–29 1448(34) 30–39 1184(27.8) 40–49 903(21.2)50–59 561(13.2)60+ 157(3.7) |
N/A | Pfizer 2500/6385(39.2) AZ 3885/6385(60.8) |
| Kim et al.40 - South Korea | Pfizer 801/969(82.7) CoronaVac 543/1129(48.1) |
Adjusted odds ratios (severe allergic reaction) for those who received CoronaVac vs Pfizer Odds ratio (95% confidence interval) 0.62 (0.36–1.06) Adjusted odds ratios (severe allergic reaction) from the second dose compared with the first dose Odds ratio (95% confidence interval) CoronaVac 1.15 (0.62–2.15) Pfizer 2.01 (1.21–3.33), p < .05 |
N/A | Followed up 2 weeks after 2nd dose | Pfizer M − 498/969(51.4) F − 471/969(48.6) CoronaVac M − 527/1129(46.7) F − 602/1129(53.3) |
Pfizer Mean(SD) 43.13(16.54) CoronaVac 46.49(24.42) |
N/A | Pfizer 869/1998(43.5) CoronaVac 1129/1998(56.5) |
| Lee et al.41 - South Korea | 434/447(97.1) | 206(46.1) | N/A | 7 days after 2 injections | F − 388(86.8) M − 59(13.2) |
Mean(SD) 40.6(10.9) |
N/A | AZ 447(100) |
| Levy et al.42 - Israel | 1st dose 711/831(85.6) 2nd dose 673/738(91.2) |
N/A | N/A | Seven days after each dose, received text message | F − 627/831(75.5) M − 204/831(24.5) |
Mean 46.5(SD 11.8) |
N/A | Pfizer 831(100) |
| Lim et al.43 - Singapore | Dose 1 3–975/1704(0.2–57.2) Dose 2 13–1195/1704(0.8–70.1) |
0(0) | 196/1704(11.5) | 1 week after both doses | F − 1340(78.6) M − 364(21.4) |
Median (Range) 35(18–76) |
N/A | Pfizer 6101(100) |
| Lotan et al.44 - Israel | 136/239(56.9) | N/A | 8/36(22.2) | Week following vaccination | F- 199/262(75.9) M − 63/262(24.0) |
Median(range) 42(22–79) |
N/A | Pfizer 425(100) |
| Low et al.45 - Singapore | 57/88(68.4) | 0(0) | 0(0) | N/A | F − 88(100) | Mean 33.2(SD 3.3) | Chinese77(87.5) Malay 6 (6.8) Indian 2 (2.3) Others 3 (3.4) |
Pfizer 88(100) |
| Maruyama et al.46 - Japan | 348/374(93.0) | N/A | N/A | 8 days after vaccination for both doses | F − 225(60.2) M − 149(39.8) |
Mean(SD) 42.44(12.71) |
N/A | Pfizer 374(100) |
| Mofaz et al.47 - Israel | 1st dose 217/1609(13.5) 2nd dose 586/1609(36.4) 3rd dose 637/1609(39.6) |
N/A | N/A | N/A | F − 854(53.08) M − 755(46.92) |
Median 52 Range 18–88 |
N/A | Pfizer 1609(100) |
| Nachtigall et al.48 - Germany | 12084/16207(74.6) | 9/16207(0.05) | N/A | Not specified | F − 6131/8269(74.1) M − 2138/8269(25.9) |
18–30: 1096/8269(13.3) 31–40: 1817/8269(30.0) 41–50: 2044/8269(24.7) 51–60: 2515/8269(30.4) >61:627/8269(7.6 Invalid: 170/8269(2.1) |
N/A | Pfizer-Pfizer 4179/8246(50.7) Moderna-Moderna 207/8246(2.5) AZ-AZ 748/8246(9.1) AZ-Pfizer 1465/8246(17.8) AZ-Moderna 284/8246(3.4) Missing information 1363/8246(16.5) |
| Nittner-Marszalska et al.49 - Poland | 1st dose 1571/1707(92.03) 2nd dose 1587/1707(92.97) |
1st dose 0(0) 2nd dose 0(0) |
1st dose Pharmacological intervention 128(7.5) Medical consultation 6(0.35) 2nd dose Pharmacological intervention 567(33.2) Medical consultation 64(3.7) |
Not specified | M − 356(20.85) F- 1351(79.15) |
20–29: 585(34.27) 30–39: 554(32.45) 40–49: 264(15.47) 50–59: 160(9.37)60+: 144(8.44) |
N/A | Pfizer 1707(100) |
| Okumura et al.50 - Japan | 252/301(83.7) | 0(0) | First dose Day 0: 1/301(0.3) Day 1: 0 (0) Day 3: 1/196(0.5) Day 7: 0(0) Second dose Day 0: 1/179(0.6) Day 1: 0(0) Day 3: 1/138(0.7) Day 7: 0(0) Third dose Day 0: 0(0) Day 1: 1/38(2.6) Day 3: 0(0) Day 7: 0(0) |
1 week follow-up after each dose | M − 128/301(42.5) F- 172/301(57.1) |
18–29 238/301(79.1) 30–69 63/301(20.9) |
N/A | Moderna 301(100) |
| Park et al.51 - South Korea | AZ 1st dose 4–205/299(1.3–68.6) across several symptoms 2nd dose 1–174/304(0.3–57.2)across several symptoms Pfizer 1st dose 0–13/19(0–68.4) across several symptoms 2nd dose 0–15/22(0–68.2) across several symptoms |
Severe interference with work 161/603(26.7) Severe interference with daily life 195/644(30.3) |
AZ 1st dose 28/299(9,4) 2nd dose 3/299(0.1) Pfizer 1st dose 1/19(5.3) 2nd dose 1/22(4.5) |
N/A | AZ 1st dose M-80(26.8) F-219(73.2) 2nd dose M-80(26.3) F-224(73.7) Pfizer 1st dose M-2(10.5) F-17(89.5) 2nd dose M-2(9.1) F-20(90.9) |
AZ 1st dose 20–29:96(32.1) 30–39:56(18.7) 40–49:54(18.1) 50–59:81(27.1) 60+:12(4.0) AZ 2nd dose 20–29: 87(28.6) 30–39: 56(18.4) 40–49: 66(21.7) 50–59: 83(27.3) 60+:12(3.9) Pfizer 1st dose 20–29:11(57.9) 30–39:4(21.1) 40–49:1(5.3) 50–59: 3(15.8) 60+:0(0) Pfizer 2nd dose 20–29:10(45.5) 30–39:7(31.8) 40–49: 3(13.6) 50–59:2(9.1) 60+: 0(0) |
N/A | AZ 368/395(93.2) Pfizer 27/395(6.8) |
| Pellegrino et al.52 - Italy | after 1st, 2nd, 3rd dose Local 26.25% (21/80), 58.75% (47/80), and 28.37% (21/74) Systemic 52.2% (42/80), 48.75% (39/80), and 43.24% (32/74) |
0(0) | N/A | N/A | M − 42/80(52.5) F − 36/80(37.5) |
Median 47.5 |
N/A | Pfizer 80(100) |
| Presby et al.53 - USA | AZ First Dose 2915/3547(84.3) AZ Second Dose 191/325(58.7) Johnson 3751/4584(81.8) Moderna First Dose 10763/17632(61.0) Moderna Second Dose 14963/16987(88.1) Pfizer First Dose 14825/29366(50.5) Pfizer Second Dose 19854/27084(73.3) |
N/A | N/A | N/A | M − 65334/99435(65.7) F − 34101/99435(34.3) |
18–29 28107(28.3) 30–39 38928(39.1) 40–54 26164(26.3) 55+ 6236(6.27) |
N/A | AZ 3782(3.8) Johnson 4584(4.6) Moderna 34619(34.8) Pfizer 56450(56.8) |
| Rahmani et al.54 - Italy | Dose 1 2–285/296(0.7–96.3) across several local and systemic reactions Dose 2 6–257/275(2.2–93.5) across several local and systemic reactions |
Dose 1 0–6/296(0–2.0) across several local and systemic reactions Dose 2 0–17/275(0–6.2) across several local and systemic reactions |
Dose 1 0(0) Dose 2 0(0) |
7 days after both doses | F − 272(53.2) M − 240(0.47) |
Mean(SD) 28.9(2.7) |
N/A | Pfizer 512(100) |
| Rolfes et al.55 - Netherlands | 13959/22184(62.9) | N/A | N/A | 6 months after vaccination | M − 3199/13959(22.9) F − 10760/13959(77.1) |
0–50 6419(46) 51–60 3090(22.1) 61–79 3539(25.3) 80+ 911(6.5) |
N/A | Pfizer 10724/22590(47.5) AZ 8778/22590(38.9) Johnson 1508/22590(6.7) Spikevax 1508/22590(6.7) Unknown 72/2590(2.8) |
| Sadarangani et al.56 - Canada | Dose 1 Not pregnant 10950/174765(6.3) Pregnant 226/5597(4.0) Dose 2 Not pregnant 10254/91131(11.3) Pregnant 227/3108(7.3) |
Dose 1 Not pregnant 733/174765(0.4) Pregnant 31/5597(0.6) Dose 2 Not pregnant 343/91131(0.4) Pregnant 19/3108(0.6) |
Y for severe reactions | N/A | Dose 1 Not pregnant Woman:170674(97.7) Man:819(0.5) Non-binary:2380(1.4) Two-spirit:148(0.1) Other: 139(0.1) Unknown:605(0.3) Pregnant Woman: 5579(99.7) Man: 3(0.1) Non-binary:12(0.2) Two-spirit:0(0) Other:1(<0.1) Unknown:2(<0.1) Dose 2 Not pregnant Woman:89176(97.9) Man:341(0.4) Non-binary:1254(1.4) Two-spirit:49(0.1) Other:69(0.1) Unknown:242(0.3) Pregnant Woman:3091(99.5) Man:1(<0.1) Non-binary:13(0.4) Two-spirit:0(0) Other:0(0) Unknown: 3(0.1) |
Dose 1 Not pregnant 15–29: 59263(33.9) 30–49: 115502(66.1) Pregnant 15–29:1417(25.3) 30–49:4180(74.7) Dose 2 Not pregnant 15–29: 26324(28.9) 30–49:64807(71.1) Pregnant 15–29:716(23.0) 30–49:2392(77.0) |
Dose 1 Not pregnant White: 47539(27.2) Black:1155(0.7) East Asian:3367(1.9) South Asian:1977(1.1) Southeast Asian:1552(0.9) Indigenous:699(0.4) Middle Eastern:1352(0.8) Latino:1392(0.8) Mixed:2714(1.6) Unknown or Other:113018(64.7) Pregnant White: 1818(32.5) Black:18(0.3) East Asian:117(2.1) South Asian:95(1.7) Southeast Asian:47(0.8) Indigenous:22(0.4) Middle Eastern:44(0.8) Latino:48(0.9) Mixed :92(1.6) Unknown or Other:3296(58.9) Dose 2 Not pregnant White:50779(55.7) Black:1169(1.3) East Asian:3471(3.8) South Asian:2041(2.2) Southeast Asian:1587(1.7) Indigenous:703(0.8) Middle Eastern:1361(1.5) Latino: 1460(1.6) Mixed:2800(3.1) Unknown or Other:25758(28.3) Pregnant White:1778(57.2) Black:22(0.7) East Asian:106(3.4) South Asian:104(3.3) Southeast Asian:45(1.4) Indigenous:21(0.7) Middle Eastern:44(1.4) Latino:50(1.6) Mixed:88(2.8) Unknown or Other:850(27.3) |
Dose 1 Not pregnant Pfizer 107121/180362(59.4) Moderna 67644/180362(37.5) Pregnant Pfizer 3414/180362(1.9) Moderna 2183/180362(1.2) Dose 2 Not pregnant Pfizer 53077/94239(56.3) Moderna 38054/94239(40.4) Pregnant Pfizer 1892/94239(2.0) Moderna 1216/94239(1.3) |
| Sen et al.57 - Various countries | 8573/10900(79) | 351/10900(3) | 38/10900(0.3) | N/A | M − 2834/10900(26) F − 8066/10900(74) |
Median(IQR) 42(30–55) |
Caucasian 4972(45) African American 83(0.7) Asian 2018(18) Hispanic 1193(11) Native American/Indigenous/Pacific Islander 342(3) Do not wish to disclose 449(4) Other 865(8) Unanswered 1672(15) |
Pfizer 4339(39) AZ 1456(13) Johnson 95(1) Moderna 910(8) Novavax 14(0.1) Covishield 1194(11) Covaxin 248(2) Sputnik 204(2) Sinopharm 1821(17) Not sure 62(0.5) Others 563(5) |
| Shimamura et al.58 - Japan | 40–1910/1990(2.0–96.0) across several local and systemic reactions | 4/1990(0.2) | N/A | 2 days following each of 3 doses | M − 418(21) F − 1572(79) |
Median 32 |
N/A | Pfizer 1990(100) |
| Song et al.59 – South Korea | 809/998(81.1) | 0(0) | N/A | N/A | F − 779(78.1) M − 219(21.9) |
20–29: 380(38.1 30–39: 216(21.6) 40–49: 185(18.5) 50–59: 180(0.18) 60–64: 37(3.7) |
N/A | AZ 998(100) |
| Supangat et al.60 - Indonesia | 68/144(47.2) | N/A | N/A | Followed for 1 week after both doses | M − 38/144(26.4) F − 106/144(73.6) |
Average age range 21–25 | N/A | CoronaVac 144(100) |
| Tani et al.61 - Japan | 278/281(98.9) | N/A | N/A | Data collected until 7 days after booster dose | F − 204/281(72.6) M − 77/281(27.4) |
Median(IQR) 41(33–50) |
N/A | Pfizer 281(100) |
| Tawinprai et al.62 - Thailand | 322/538(59.9) | 0–41(7.62) across various local and systemic reactions |
N/A | Data collected until 7 days after vaccination | F − 517/794(65.1) | Median(IQR) 40(30–57) |
N/A | AZ 794(100) |
| Toussia-Cohen et al.63 - Israel | Second vaccination 73/78(93.6) Third vaccination 61/84(72.6) |
Second vaccination 0(0) Third vaccination 0(0) |
Second vaccination 0(0) Third vaccination 0(0) |
N/A | Second vaccinationF-78(100) Third vaccinationF-84(100) |
Second vaccination Mean 32.85(SD3.49) Third vaccination 33.23(3.95) |
N/A | Second vaccination Pfizer-78(100) Third vaccination Pfizer-84(100) |
| Vigezzi et al.64 - Italy | Male 376/720 (52.2) Female 1,286/1,939(66.3) |
285/2,659 (10.7) | N/A | N/A | F − 2600/5668(45.9) M − 3068/5668(54.1) |
Median 42 Range 19–76 |
N/A | Pfizer 5668(100) |
| Walmsley et al.65 - Canada | First dose 26/37(0.70) Second dose 906/955(94.9) |
N/A | N/A | 38(4%) reported persistent adverse events thought related to the vaccine at month 1, decreasing to 10(1%) at month five. | F or non-binary 760/1193(63.7) M 433/1193(36.3) |
30–50 41[36, 45] 70+ 73[71, 76] |
Arab/West Indian 10/1193(0.8) Black 20/1193(1.7) Indigenous 5/1193(0.4) Latin American 7/1193(0.6) South Asian 15/1193(1.3) Southeast Asian 32/1193(2.7) White 1045/1193(87.6) Other 52/1193(4.4) |
2 doses Pfizer 733(61.4) 2 doses Moderna 131(11.0) 1 dose Pfizer/1 dose Moderna 201(16.8) 1 dose AZ/1 dose Pfizer or Moderna 69(5.8) Other or unknown 36(3.0) |
| Warkentin et al.66 - USA | ChAdOx1/ChAdOx1 475/552(86) ChAdOx1/mRNA 1382/2383(58) mRNA/mRNA 4721/6212(0.76) |
N/A | ChAdOx1/ChAdOx1 69/462(14.9) ChAdOx1/mRNA 287/1638(17.5) mRNA/mRNA 796/5004(15.9) |
Followed up to 56 days after vaccination | F − 4661/8145(57.2) M − 3483/8145(42.8) Diverse - 1/8145(0.01) |
ChAdOx1/ChAdOx1 Mean(SD) 55.87(15.3) ChAdOx1/mRNA 47.6(13.89) mRNA/mRNA 45.87(15.14) |
N/A | ChAdOx1/ChAdOx1 487/8145(6.0) ChAdOx1/mRNA 1943/8145(23.9) mRNA/mRNA 5715/8145(70.2) |
| Wei et al.67 - China | Homologous Vero Cell Booster Group 62/635(9.8) Homologous CHO Cell Booster Group 13/75(17.3) Heterologous Mixed Vaccines Booster Group 17/82(20.7) |
N/A | N/A | N/A | F − 597/792 (75.4) M − 195/792(24.6) |
Ages 18–60 | N/A | Homologous Vero Cell Booster Group 635/792(80.1) Homologous CHO Cell Booster Group 75/792(9.5) Heterologous Mixed Vaccines Booster Group 82/792(10.4) |
| Yamazaki et al.68 - Japan | 1st dose 2134/2406(88.7) 2nd dose 2168/2347(92.4) |
1st dose 27(1.1) 2nd dose 154(6.6) |
1st dose 9(0.4) 2nd dose 13(0.6) |
N/A | 1st dose M − 921(38.3) F − 1485(61.7) 2nd dose M-898(38.3) F-1449(61.7) |
1st dose 20–29:657(27.3) 30–39:772(32.1) 40–49:551(22.9) 50–59:335(13.9) 60+:91(3.8) 2nd dose 20–29: 627(26.7)30–39: 750(32.0)40–49: 541(23.1)50–59: 339(14.4)60+: 90(3.8) |
N/A | Pfizer 1st dose 2406(100) 2nd dose 2347(100) |
| Yechezkel et al.69 - Israel | Retrospective Cohort 2–203(<1–1.1) |
Retrospective Cohort 0–170 (0–1) |
N/A | N/A | Prospective First booster M: 866/1785(48.5) F: 919/1785(51.5) Unspecified: 0/1785(0) Second booster M: 348/699(48.8) F: 350/699(50.2) Unspecified: 1/699(<1) First and Second Booster M: 215/446(48.2) F: 231/446(51.8) Unspecified: 0/446(0) Retrospective First booster M: 45208/94169(48.0) F: 48961/94169(52.0) Unspecified: 0/94169(0) First and Second Booster M: 8879/17814(49.8) F: 8935/1781(50.2) Unspecified: 0/1781(0) |
Prospective Median(IQR) First booster 52(34–61) Second booster 62(53–68) First and second booster 64(57–70) Retrospecitve First booster 47(31–61) First and second booster 69(62–76) |
Prospective First booster Jewish 1678(94) Arab 18(1.0) Unspecified89(5.0) Second Booster Jewish 672(96.1) Arab 1(<1) Unspecified26(3.7) First and second booster Jewish 434(97.3) Arab 0(0) Unspecified12(2.7) Retrospective First booster Jewish 90106(95.7) Arab 4046(4.3) Unspecified17(<1) First and second booster Jewish 17513(98.3) Arab 300(1.7) Unspecified1(<1) |
Pfizer 254698(100) |
| Zhang et al.70 - China | Female 0–124/1107(0–11.2) across several systemic and local reactions Male 0–25/290(0–8.6) across several systemic and local reactions |
N/A | N/A | 1 week following 2 doses | F − 1107/1397(79.2) M − 290/1397(20.8) |
F – Mean (SD) 34.7(8.6) M – Mean (SD) 38.7(9.9) |
N/A | CoronaVac 3013(100) |
| Zhu et al.71 - China | Female 0–124/1107(0–11.2) across several systemic and local reactions Male 0–25/290(0–8.6) across several systemic and local reactions |
N/A | N/A | 1 week following 2 doses | F − 1107/1397(79.2) M − 290/1397(20.8) |
F – Mean (SD) 34.7(8.6) M – Mean (SD) 38.7(9.9) |
N/A | CoronaVac 3013(100) |